Search company, investor...

GRIT Biotechnology

Founded Year



Series A - II | Alive

Total Raised


About GRIT Biotechnology

GRIT Biotechnology is a pharmaceutical company dedicated to developing cell therapy drugs for solid tumor patients.

Headquarters Location

Zhuhai, Guangdong,


Missing: GRIT Biotechnology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GRIT Biotechnology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing GRIT Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GRIT Biotechnology is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest GRIT Biotechnology News

Grit Bio Closes Series A+ Round for its Cell Therapy Oncology Therapies

Jul 16, 2021

publication date: Jul 16, 2021 Grit Biotechnology, a two-year-old Shanghai cell therapy company, closed a Series A+ round to develop its Tumor Infiltrating Lymphocytes (TIL) therapies. Its leading program is GT101, a genetically unmodified TIL product that is currently being tested at a multi-centered clinical trial in China for solid malignancy indications. The round was led by GL Ventures, the VC arm of Hillhouse Group, with participation from Apricot Capital and Junshi Bio, as well as continued support from existing shareholders, Decheng Capital and Matrix Partners. More details.... Share this with colleagues: Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today? If you are already a subscriber, please login. If you believe you should have received this message in error, please contact us .

GRIT Biotechnology Frequently Asked Questions (FAQ)

  • When was GRIT Biotechnology founded?

    GRIT Biotechnology was founded in 2019.

  • Where is GRIT Biotechnology's headquarters?

    GRIT Biotechnology's headquarters is located at Zhuhai.

  • What is GRIT Biotechnology's latest funding round?

    GRIT Biotechnology's latest funding round is Series A - II.

  • How much did GRIT Biotechnology raise?

    GRIT Biotechnology raised a total of $15.27M.

  • Who are the investors of GRIT Biotechnology?

    Investors of GRIT Biotechnology include Matrix Partners China, Decheng Capital, Hillhouse Capital Management, Shanghai Junshi Biosciences, Apricot Capital and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.